OncXerna Therapeutics to Participate at the Upcoming Investor Conferences

NEXT STORY
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
PREV STORY
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Basilea berichtet über Präsentationen zu Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Europäischen Kongress für Klinische Mikrobiologie und Infektionskrankheiten (ECCMID)

author_avatar
NASDAQ Market News

Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

author_avatar
NASDAQ Market News

Weinberg Foundation Employees Announce $660,000 in Grants

author_avatar
NASDAQ Market News